Cytonics

We took one of Nature’s beautiful creations and iterated on it…

At Cytonics, we didn’t invent Alpha-2-Macroglobulin (A2M).

Nature did.

What we did was unlock its potential.

A2M is a naturally occurring protein that neutralizes the enzymes responsible for cartilage destruction.

Our early experiments showed that when A2M is concentrated and injected directly into the joint, it can dramatically slow the progression of osteoarthritis (OA).

But the natural A2M protein had limits:
➡️ It’s hard to concentrate from patients’ blood at scale
➡️ There is patient-to-patient variability in natural A2M levels
➡️ And it wasn’t optimized for the specific proteases involved in OA

So we took evolution’s raw material and refined it.

Enter: CYT-108, our precision-engineered “Super A2M.”

We modified A2M’s bait region to improve its ability to trap the full spectrum of cartilage-degrading proteases — including serine, cysteine, and metalloproteinases. We optimized its structure for large-scale, GMP-compliant production. And we designed it to stay localized in the joint, reducing off-target exposure and avoiding systemic side effects.

The result? A recombinant biologic that combines broad-spectrum protease inhibition with real-world clinical utility.

CYT-108 isn’t just based on Nature.

It’s a perfected version of nature’s blueprint — built for patients, validated by science, and protected by 25 issued patents.

This is what innovation in regenerative medicine looks like.

Want to join us as we advance CYT-108 into Phase 2?

🔗 Become a shareholder today.

Appreciatively,

Joey Bose

President & CEO

Reg A Disclaimer

This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. You may obtain a copy of the offering circular here.